Indaptus Therapeutics, Inc. Stock-Based Compensation
Indaptus Therapeutics, Inc. (INDP) reported Stock-Based Compensation of $162.90 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Indaptus Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was -$64.28K, a 135.56% decline year-over-year.
- Indaptus Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $227.18K, a 5.69% decline year-over-year.
- Indaptus Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $785.81K, a 158.39% increase year-over-year.
- Indaptus Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $150.61K, a 66.09% decline year-over-year.
- Indaptus Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.36M, a 41.10% decline from fiscal 2024.
- Indaptus Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $2.31M, a 22.26% decline from fiscal 2023.
- Indaptus Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $2.97M, a 0.29% increase from fiscal 2022.
- Indaptus Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $2.96M, a 95.81% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$64.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $162.90K 10-Q · filed 2026-08-13 | $948.71K derived: sum of 3 quarters · filed 2026-08-13 | $1.10M derived: sum of 4 quarters · filed 2026-08-13 | |
| 2026-03-31 | $227.18K 10-Q · filed 2026-05-15 | $1.01M derived: sum of 2 quarters · filed 2026-05-15 | $1.16M derived: sum of 3 quarters · filed 2026-05-15 | $1.34M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-12-31 | $785.81K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $936.43K derived: sum of 2 quarters · filed 2026-03-17 | $1.12M derived: sum of 3 quarters · filed 2026-03-17 | $1.36M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $150.61K 10-Q · filed 2025-11-12 | $331.38K derived: sum of 2 quarters · filed 2025-11-12 | $572.27K 10-Q · filed 2025-11-12 | $876.39K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-06-30 | $180.76K 10-Q · filed 2025-08-13 | $421.65K 10-Q · filed 2026-08-13 | $725.78K derived: sum of 3 quarters · filed 2026-05-15 | $1.17M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2025-03-31 | $240.89K 10-Q · filed 2026-05-15 | $545.01K derived: sum of 2 quarters · filed 2026-05-15 | $989.20K derived: sum of 3 quarters · filed 2026-05-15 | $1.77M derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $304.12K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $748.31K derived: sum of 2 quarters · filed 2026-03-17 | $1.53M derived: sum of 3 quarters · filed 2026-03-17 | $2.31M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $444.18K 10-Q · filed 2025-11-12 | $1.23M derived: sum of 2 quarters · filed 2025-11-12 | $2.00M 10-Q · filed 2025-11-12 | $2.75M derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $782.85K 10-Q · filed 2025-08-13 | $1.56M 10-Q · filed 2025-08-13 | $2.30M derived: sum of 3 quarters · filed 2025-08-13 | $3.07M derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $774.69K 10-Q · filed 2025-05-14 | $1.52M derived: sum of 2 quarters · filed 2025-05-14 | $2.29M derived: sum of 3 quarters · filed 2025-05-14 | $3.01M derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $745.52K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.51M derived: sum of 2 quarters · filed 2025-03-13 | $2.24M derived: sum of 3 quarters · filed 2025-03-13 | $2.97M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $764.80K 10-Q · filed 2024-11-12 | $1.49M derived: sum of 2 quarters · filed 2024-11-12 | $2.22M 10-Q · filed 2024-11-12 | $2.86M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $728.47K 10-Q · filed 2024-08-12 | $1.46M 10-Q · filed 2024-08-12 | $2.09M derived: sum of 3 quarters · filed 2024-08-12 | $2.68M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $727.14K 10-Q · filed 2024-05-08 | $1.36M derived: sum of 2 quarters · filed 2024-05-08 | $1.95M derived: sum of 3 quarters · filed 2024-05-08 | $2.85M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $637.63K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $1.22M derived: sum of 2 quarters · filed 2024-03-13 | $2.13M derived: sum of 3 quarters · filed 2024-03-13 | $2.96M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $584.04K 10-Q · filed 2023-11-06 | $1.49M derived: sum of 2 quarters · filed 2023-11-06 | $2.32M 10-Q · filed 2023-11-06 | $2.99M derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | $904.39K 10-Q · filed 2023-08-14 | $1.74M 10-Q · filed 2023-08-14 | $2.41M derived: sum of 3 quarters · filed 2023-08-14 | $3.20M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $831.18K 10-Q · filed 2023-05-11 | $1.50M derived: sum of 2 quarters · filed 2023-05-11 | $2.30M derived: sum of 3 quarters · filed 2023-05-11 | $2.32M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $673.80K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $1.47M derived: sum of 2 quarters · filed 2023-03-17 | $1.49M derived: sum of 3 quarters · filed 2023-03-17 | $1.51M 10-K · filed 2023-03-17 | |
| 2021-09-30 | $795.34K 10-Q · filed 2022-11-10 | $816.01K derived: sum of 2 quarters · filed 2022-11-10 | $836.46K 10-Q · filed 2022-11-10 | $859.54K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $20.67K 10-Q · filed 2022-08-08 | $41.12K 10-Q · filed 2022-08-08 | $208.00K 10-Q · filed 2021-08-16 | $64.21K derived: sum of 3 quarters · filed 2022-08-08 | -$674.92K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $20.45K 10-Q · filed 2022-05-12 | $43.53K derived: sum of 2 quarters · filed 2022-05-12 | -$695.60K derived: sum of 3 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $23.09K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$716.04K derived: sum of 2 quarters · filed 2022-03-21 | $139.96K 10-K · filed 2022-03-21 | ||
| 2020-09-30 | -$739.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $116.87K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $856.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |